Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects

BACKGROUND: To prospectively analyze the efficacy of uromune® in the prevention of uncomplicated recurrent urinary tract infections at 3 and 6 months, and according to gender and menopause. METHODS: From September 2011 to December 2017 uromune® was administered sublingually every 24 h along 3 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramírez Sevilla, Cristóbal, Gómez Lanza, Esther, Manzanera, Juan Llopis, Martín, Jose Antonio Romero, Sanz, Miguel Ángel Barranco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819445/
https://www.ncbi.nlm.nih.gov/pubmed/31660885
http://dx.doi.org/10.1186/s12879-019-4541-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819445/
https://www.ncbi.nlm.nih.gov/pubmed/31660885
http://dx.doi.org/10.1186/s12879-019-4541-y

Ejemplares similares